|
CA3024523A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
UA125802C2
(uk)
*
|
2017-11-15 |
2022-06-08 |
Міраті Терапьютікс, Інк. |
Інгібітори kras g12c
|
|
MA52501A
(fr)
*
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
EP3790551A4
(en)
|
2018-05-07 |
2022-03-09 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
US20210230170A1
(en)
*
|
2018-08-31 |
2021-07-29 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
HRP20250480T1
(hr)
|
2018-09-10 |
2025-06-20 |
Mirati Therapeutics, Inc |
Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
|
|
EP3849536A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CA3111977A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CA3111980A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US12065430B2
(en)
|
2018-10-26 |
2024-08-20 |
Taiho Pharmaceutical Co., Ltd. |
Indazole compound or salt thereof
|
|
EP3735299B1
(en)
|
2018-11-09 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Fused ring compounds
|
|
US12377101B2
(en)
*
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP7592601B2
(ja)
|
2019-01-10 |
2024-12-02 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
EP4249000A3
(en)
|
2019-02-12 |
2023-12-27 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
|
BR112021017408A2
(pt)
|
2019-03-05 |
2022-01-18 |
Astrazeneca Ab |
Compostos tricíclicos fundidos úteis como agentes anticancerosos
|
|
CN113874374B
(zh)
*
|
2019-05-24 |
2024-12-27 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CN118745177A
(zh)
|
2019-05-29 |
2024-10-08 |
上海翰森生物医药科技有限公司 |
含氮杂环类衍生物调节剂、其制备方法和应用
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药（苏州）股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
WO2021023154A1
(zh)
*
|
2019-08-02 |
2021-02-11 |
上海济煜医药科技有限公司 |
四并环类化合物及其制备方法和应用
|
|
CN112341457A
(zh)
*
|
2019-08-07 |
2021-02-09 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN114616232A
(zh)
*
|
2019-09-06 |
2022-06-10 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
EP4031542B1
(en)
*
|
2019-09-18 |
2025-10-15 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
MX2022003537A
(es)
*
|
2019-09-24 |
2022-07-11 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
US20210094919A1
(en)
*
|
2019-09-25 |
2021-04-01 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
CA3153456A1
(en)
|
2019-10-02 |
2021-04-08 |
Stefanie Fluckiger-Mangual |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
US20230257374A1
(en)
*
|
2019-10-10 |
2023-08-17 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
US11697657B2
(en)
|
2019-10-28 |
2023-07-11 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of KRAS G12C mutant
|
|
EP4328229A3
(en)
*
|
2019-10-30 |
2024-10-02 |
Genfleet Therapeutics (Shanghai) Inc. |
Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
|
|
EP4054720A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021088458A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
|
KR20220109408A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
CN114901286B
(zh)
|
2019-11-27 |
2024-05-10 |
特普医药公司 |
涉及二芳基巨环化合物的组合疗法
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
WO2021109737A1
(zh)
*
|
2019-12-02 |
2021-06-10 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
TWI765448B
(zh)
*
|
2019-12-11 |
2022-05-21 |
美商美國禮來大藥廠 |
Kras g12c抑制劑
|
|
CN113004269B
(zh)
*
|
2019-12-19 |
2024-11-05 |
首药控股(北京)股份有限公司 |
Kras-G12C抑制剂杂环化合物
|
|
MX2022007527A
(es)
*
|
2019-12-19 |
2022-07-19 |
Jacobio Pharmaceuticals Co Ltd |
Inhibidores de proteinas kras mutantes.
|
|
WO2021120890A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
US11702418B2
(en)
|
2019-12-20 |
2023-07-18 |
Mirati Therapeutics, Inc. |
SOS1 inhibitors
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
WO2021139748A1
(en)
|
2020-01-08 |
2021-07-15 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Spirocyclic tetrahydroquinazolines
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
AU2021224733A1
(en)
*
|
2020-02-20 |
2022-09-01 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as KRAS inhibitors
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN113637005B
(zh)
*
|
2020-02-24 |
2024-05-24 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
WO2021180181A1
(zh)
*
|
2020-03-12 |
2021-09-16 |
南京明德新药研发有限公司 |
嘧啶并杂环类化合物及其应用
|
|
WO2021218939A1
(zh)
*
|
2020-04-28 |
2021-11-04 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
|
TW202144349A
(zh)
*
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
|
|
WO2021231526A1
(en)
*
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
EP4157837B1
(en)
|
2020-06-02 |
2024-12-18 |
Boehringer Ingelheim International GmbH |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
US20230212170A1
(en)
*
|
2020-06-04 |
2023-07-06 |
Shanghai Antengene Corporation Limited |
Inhibitors of kras g12c protein and uses thereof
|
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
|
WO2021259972A1
(en)
|
2020-06-24 |
2021-12-30 |
Boehringer Ingelheim International Gmbh |
Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor
|
|
WO2021260111A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
JP2023538060A
(ja)
*
|
2020-08-17 |
2023-09-06 |
貝達薬業股▲ふん▼有限公司 |
二環化合物、それを含む組成物、及びそれらの使用
|
|
EP4203952A4
(en)
|
2020-08-28 |
2024-12-11 |
Kumquat Biosciences Inc. |
HETEROCYCLIC COMPOUNDS AND USES THEREOF
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
JP2023540388A
(ja)
|
2020-09-11 |
2023-09-22 |
メッドシャイン ディスカバリー インコーポレイテッド |
アゼチジン置換化合物の結晶形
|
|
CN116601151A
(zh)
*
|
2020-09-11 |
2023-08-15 |
米拉蒂治疗股份有限公司 |
Kras g12c抑制剂的晶型
|
|
BR112023004569A2
(pt)
*
|
2020-09-11 |
2023-04-04 |
Mirati Therapeutics Inc |
Formas cristalinas de um inibidor de kras g12c
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022081655A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Accutar Biotechnology, Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
|
WO2022087270A1
(en)
|
2020-10-23 |
2022-04-28 |
Mirati Therapeutics, Inc. |
Methods for treatment of lung cancers
|
|
TW202233607A
(zh)
*
|
2020-10-30 |
2022-09-01 |
瑞士商諾華公司 |
Ｋｒａｓ ｇ１２ｃ抑制劑化合物之新結晶形式
|
|
CN120887884A
(zh)
|
2020-11-06 |
2025-11-04 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的KRas抑制剂
|
|
EP4247807A4
(en)
*
|
2020-11-23 |
2024-10-16 |
Merck Sharp & Dohme LLC |
6,7-DIHYDRO-PYRANO[2,3-D PYRIMIDINE AS INHIBITORS OF THE KRAS G12C MUTANT
|
|
CN114591319B
(zh)
*
|
2020-12-04 |
2024-06-28 |
江苏先声药业有限公司 |
四氢吡啶并嘧啶类衍生物及其用途
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
MX2023007084A
(es)
|
2020-12-15 |
2023-08-30 |
Mirati Therapeutics Inc |
Inhibidores de pan-kras de azaquinazolina.
|
|
WO2022133038A1
(en)
*
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022129925A1
(en)
|
2020-12-18 |
2022-06-23 |
Amphista Therapeutics Limited |
Novel bifunctional molecules for targeted protein degradation
|
|
TWI795129B
(zh)
*
|
2020-12-18 |
2023-03-01 |
大陸商正大天晴藥業集團股份有限公司 |
吡啶并嘧啶酮類化合物
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
KR20230127256A
(ko)
*
|
2020-12-22 |
2023-08-31 |
노파르티스 아게 |
Kras g12c 억제제를 포함하는 약제학적 조합물 및 암의치료를 위한 kras g12c 억제제의 용도
|
|
CN114716436A
(zh)
*
|
2021-01-04 |
2022-07-08 |
广州百霆医药科技有限公司 |
Kras g12c突变抑制剂及其用途
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022165142A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
BR112023015359A2
(pt)
*
|
2021-02-01 |
2023-11-14 |
Medshine Discovery Inc |
Composto de pirimidopirano
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
WO2022187527A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Nikang Therapeutics, Inc |
Quinazoline nitrile derivatives as kras inhibitors
|
|
JP2024509625A
(ja)
|
2021-03-15 |
2024-03-04 |
ノバルティス アーゲー |
ベンゾイソオキサゾール誘導体及びその使用
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
CN116157400B
(zh)
*
|
2021-03-30 |
2024-10-22 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
AU2022253455A1
(en)
|
2021-04-08 |
2023-11-02 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors for the treatment of cancer
|
|
US20240238294A1
(en)
|
2021-04-09 |
2024-07-18 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
CN117203208A
(zh)
*
|
2021-04-23 |
2023-12-08 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
BR112023022819A2
(pt)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
|
|
TW202313048A
(zh)
*
|
2021-05-19 |
2023-04-01 |
美商建南德克公司 |
組合療法
|
|
CN117813306A
(zh)
*
|
2021-05-22 |
2024-04-02 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物，及其制备和治疗用途
|
|
WO2022251193A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2022251576A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
JP2024521979A
(ja)
*
|
2021-05-28 |
2024-06-04 |
大鵬薬品工業株式会社 |
Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照
|
|
JP7668908B2
(ja)
|
2021-06-09 |
2025-04-25 |
イーライ リリー アンド カンパニー |
Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2022262797A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Shanghai Antengene Corporation Limited |
Combination of an erk inhibitor and a kras inhibitor and uses thereof
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
US12441727B2
(en)
|
2021-07-07 |
2025-10-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
CN117751116A
(zh)
*
|
2021-07-07 |
2024-03-22 |
微境生物医药科技(上海)有限公司 |
作为KRas G12D抑制剂的稠环化合物
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
CN117677398A
(zh)
|
2021-07-27 |
2024-03-08 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
|
CN113527294A
(zh)
*
|
2021-08-25 |
2021-10-22 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US20240400558A1
(en)
*
|
2021-09-09 |
2024-12-05 |
Mirati Therapeutics, Inc. |
Processes and intermediates for synthesis of adagrasib
|
|
WO2023051586A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
先声再明医药有限公司 |
Kras g12d抑制剂化合物及其制备方法和应用
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
KR20240089594A
(ko)
|
2021-10-22 |
2024-06-20 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
|
|
MX2024005228A
(es)
|
2021-11-05 |
2024-07-24 |
Frontier Medicines Corp |
Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
|
|
US12110276B2
(en)
|
2021-11-24 |
2024-10-08 |
Genentech, Inc. |
Pyrazolo compounds and methods of use thereof
|
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
IL312905A
(en)
|
2021-12-01 |
2024-07-01 |
Boehringer Ingelheim Int |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2023098425A1
(zh)
*
|
2021-12-02 |
2023-06-08 |
上海和誉生物医药科技有限公司 |
一种kras抑制剂及其制备和在药学上的应用
|
|
EP4448526A1
(en)
|
2021-12-17 |
2024-10-23 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2024546642A
(ja)
|
2021-12-22 |
2024-12-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの処置のための複素芳香族化合物
|
|
US20250161305A1
(en)
|
2021-12-28 |
2025-05-22 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
|
CN114409653A
(zh)
*
|
2021-12-31 |
2022-04-29 |
苏州闻天医药科技有限公司 |
一种桥环并嘧啶并环类化合物及其用途
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4476202A1
(en)
*
|
2022-02-11 |
2024-12-18 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
KR20240163107A
(ko)
|
2022-03-11 |
2024-11-18 |
컴쿼트 바이오사이언시즈 인크. |
헤테로환 화합물 및 이의 용도
|
|
US12351591B2
(en)
|
2022-03-25 |
2025-07-08 |
Eli Lilly And Company |
KRas inhibitors
|
|
CA3244999A1
(en)
|
2022-03-31 |
2025-06-13 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
US20250295664A1
(en)
|
2022-04-04 |
2025-09-25 |
Sanofi |
Therapeutic combination of kras g12c inhibitor and tead inhibitor
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
CA3254782A1
(en)
*
|
2022-04-18 |
2023-10-26 |
Mirati Therapeutics, Inc. |
PROCESSES AND INTERMEDIARIES FOR ADAGRASIB SYNTHESIS
|
|
IL316253A
(en)
|
2022-05-06 |
2025-01-01 |
Chugai Pharmaceutical Co Ltd |
A cyclic compound with selective KRAS inhibitory effect on HRAS and NRAS
|
|
CN114907387B
(zh)
*
|
2022-05-26 |
2023-11-10 |
中山大学 |
嘧啶并吡咯类kras抑制剂及其制备方法与应用
|
|
CN117164526A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
US20250353844A1
(en)
*
|
2022-06-10 |
2025-11-20 |
Bristol-Myers Squibb Company |
Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
|
|
CN120504682A
(zh)
|
2022-06-10 |
2025-08-19 |
锐新医药公司 |
大环ras抑制剂
|
|
IL318647A
(en)
|
2022-08-05 |
2025-03-01 |
Kumquat Biosciences Inc |
Heterocyclic compounds and their uses
|
|
EP4573095A1
(en)
|
2022-08-17 |
2025-06-25 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
CA3264627A1
(en)
|
2022-08-19 |
2024-02-22 |
Mirati Therapeutics, Inc. |
SOLID PHARMACEUTICAL COMPOSITIONS OF ADAGRASIB
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
IL320913A
(en)
|
2022-11-21 |
2025-07-01 |
Treeline Biosciences Inc |
Spirocyclic dihydropyranopyrimidine KRAS inhibitors
|
|
CN116789609A
(zh)
*
|
2023-03-03 |
2023-09-22 |
南京优氟医药科技有限公司 |
一种(r)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
CN116768804A
(zh)
*
|
2023-03-15 |
2023-09-19 |
南京优氟医药科技有限公司 |
一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
KR20250164300A
(ko)
|
2023-03-30 |
2025-11-24 |
일라이 릴리 앤드 캄파니 |
KRas 억제제
|
|
US20240368193A1
(en)
|
2023-03-31 |
2024-11-07 |
Eli Lilly And Company |
Kras inhibitors
|
|
EP4656193A1
(en)
|
2023-04-06 |
2025-12-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
AU2024253668A1
(en)
|
2023-04-07 |
2025-11-13 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
KR20250169290A
(ko)
|
2023-04-14 |
2025-12-02 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
|
|
WO2024229444A2
(en)
*
|
2023-05-04 |
2024-11-07 |
Frontier Medicines Corporation |
Mutant kras inhibitors and uses thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024246114A1
(en)
|
2023-05-31 |
2024-12-05 |
Boehringer Ingelheim International Gmbh |
Survivin as a biomarker for predicting the responsiveness of cancer treatment
|
|
CN116675690A
(zh)
*
|
2023-06-02 |
2023-09-01 |
北京康立生医药技术开发有限公司 |
一种肺癌治疗药物的制备方法
|
|
CN121219016A
(zh)
|
2023-06-02 |
2025-12-26 |
第一三共株式会社 |
抗-her3抗体-药物缀合物和rasg12c抑制剂的组合
|
|
CN116478141B
(zh)
*
|
2023-06-20 |
2023-10-24 |
药康众拓(江苏)医药科技有限公司 |
氘代kras抑制剂药物及用途
|
|
TW202502779A
(zh)
|
2023-06-30 |
2025-01-16 |
美商金橘生物科技公司 |
取代的雜芳族胺及其用途
|
|
WO2025019688A2
(en)
*
|
2023-07-20 |
2025-01-23 |
Mirati Therapeutics, Inc. |
Crystalline forms of salts of adagrasib
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250101043A1
(en)
|
2023-09-27 |
2025-03-27 |
Eli Lilly And Company |
Kras inhibitors
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
US20250205238A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|